![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsors and Collaborators: |
Hospital Authority, Hong Kong Eli Lilly and Company |
---|---|
Information provided by: | Hospital Authority, Hong Kong |
ClinicalTrials.gov Identifier: | NCT00563160 |
To study the activity of chemotherapy with Gemzar-carboplatin in the preoperative setting for operable stages of non-small-cell lung cancer and to identify novel molecular markers correlated with chemosensitivity and prognosis
Condition | Intervention | Phase |
---|---|---|
Lung Neoplasms |
Drug: gemcitabine, carboplatin Procedure: surgery |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | Phase II Study of the Response Rate of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-Small Cell Lung Cancer Before Surgery |
Estimated Enrollment: | 50 |
Study Start Date: | May 2005 |
Estimated Study Completion Date: | February 2007 |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Contact: Patricia Poon, Dr | (852) 2958 2310 | pcm0806@netvigator.com |
China | |
Queen Elizabeth Hospital | Recruiting |
Hong Kong, China | |
Sub-Investigator: Che Mun Poon, Dr | |
Sub-Investigator: Chun Key Law, Dr | |
Sub-Investigator: Roger Ngan, Dr | |
Sub-Investigator: Chung Kong Kwan, Dr | |
Sub-Investigator: Cheuk Kin Lo, Dr | |
Sub-Investigator: Johnny Chan, Dr | |
Sub-Investigator: TK Au Yong, Dr | |
Sub-Investigator: Ting Lok Kwan, Dr | |
Sub-Investigator: Stella Cheung, Dr | |
Sub-Investigator: Timothy Yip |
Principal Investigator: | Siu Kie Au, Dr | Department of Clinical Oncology, Queen Elizabeth Hospital |
Study ID Numbers: | (193-h)in QE/EC/I, HARECCTR0500015, 000904, B9E-IH-O333 |
Study First Received: | November 21, 2007 |
Last Updated: | June 23, 2009 |
ClinicalTrials.gov Identifier: | NCT00563160 History of Changes |
Health Authority: | Hong Kong: Ethics Committee |
lung cancer |
Thoracic Neoplasms Antimetabolites Anti-Infective Agents Immunologic Factors Carboplatin Immunosuppressive Agents Antiviral Agents Carcinoma |
Radiation-Sensitizing Agents Respiratory Tract Diseases Lung Neoplasms Lung Diseases Non-small Cell Lung Cancer Gemcitabine Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial |
Thoracic Neoplasms Antimetabolites Anti-Infective Agents Antimetabolites, Antineoplastic Molecular Mechanisms of Pharmacological Action Immunologic Factors Antineoplastic Agents Physiological Effects of Drugs Neoplasms by Site Respiratory Tract Diseases Lung Neoplasms Therapeutic Uses Gemcitabine |
Respiratory Tract Neoplasms Neoplasms by Histologic Type Enzyme Inhibitors Carboplatin Antiviral Agents Immunosuppressive Agents Pharmacologic Actions Carcinoma Neoplasms Radiation-Sensitizing Agents Lung Diseases Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial |